The accumulation of EGFR in the cytoplasm was noted consistently and was in agreement with prior findings that emerged from the treatment of various EGFR mutant cancers with Tyr kinase inhibitors where the cytoplasmic accumulation of EGFR was used as a predictor of clinical efficacy (de Wit et al., 2020). Here, EGFR is linked to cancer.